immune mediated. This is evidenced by the observations of a reduced risk of leukaemia relapse after allogeneic BMT Anti-leukaemia activity after allogeneic bone marrow when compared with autologous or syngeneic BMT. Furtransplantation has been studied extensively but its antithermore, an increased incidence of leukaemic relapse has gen specificity and effector cell phenotype remain been reported after aggressive GVHD prophylaxis with unknown. Here we report a study in three recipients of cyclosporin A, 1 or lymphocyte depletion. The association autologous bone marrow transplantation done as part between GVHD and the graft-versus-leukaemia activity of of the treatment for acute leukaemia, in whom we were allogeneic BMT is strong and has led to a number of workable to detect innate specific anti-leukaemia activity ers concluding that GVL might be inseparable from GVHD. post-transplant. One patient maintained selective cellHowever, the lymphocyte subsets responsible for GVHD mediated cytolytic activity against her autologous leuand GVL remain to be elucidated in man despite intensive kaemic cells in the absence of cytolysis of her normal efforts. 
The role of the immune response in the control and eradiIn this study we have followed three patients for up to cation of leukaemia remains controversial but there is 3 years after ABMT for acute leukaemia. In all cases we increasing evidence that the principal mechanism of cure have tested their immune reactivity in vitro after ABMT after intensive chemotherapy and allogeneic BMT is against both their original leukaemic cells and their normal BMMC which were used for the autologous transplant.
Materials and methods
fraction was recovered and incubated in triplicate with labelled targets at a ratio of 10:1 for 4 h. After the incubation period the cells were resuspended in a solution of 1 g/ml Three patients were studied after ABMT, the clinical details of whom are presented in Table 1 . Peripheral blood and propidium iodide (Sigma) in PBS and analysed by flow cytometry (FACScan or FACS Vantage; Becton Dickinson, bone marrow samples were obtained prior to ABMT after informed consent. These samples included presentation of Oxford, UK). At least 10 000 target cells were acquired with 1024 channel resolution after electronic gating on leukaemic blasts and autologous remission bone marrow. Mononuclear cells were isolated by density gradient separgreen or red fluorescence and the mean proportion of propidium iodide-positive cells from the triplicate samples ation (Lymphoprep; Nyegaard, Oslo, Norway) and cryopreserved in RPMI 1640/50% fetal calf serum (FCS)/10%
determined. Background target cell death was determined from cells incubated in the absence of effector cells. DMSO (Sigma, Poole, UK) in the vapour phase of liquid nitrogen (all tissue culture reagents were purchased from Cell-mediated cytotoxicity was reported as percentage killing over background cell death averaged from the Gibco (Paisley, UK)). After ABMT, heparinised blood samples were collected at regular intervals and tested three samples: immediately or cryopreserved as above for future analysis.
Mean (% necrotic in test − % background necrosis). Before testing for anti-leukaemia activity all patient samples were tested against the erythroleukaemic cell line This was calculated for both leukaemic and normal autolog-K562 to confirm NK cell function. No samples were tested ous target cells which were used as negative controls to against autologous leukaemic cells that had not been shown confirm leukaemia specificity. Leukaemia-specific killing to lyse K562.
was determined by subtracting the percent cytolysis of Cell-mediated cytotoxicity was determined by a dyeremission BMMC from the percent lysis of leukaemic exclusion assay.
7,12-15 Autologous leukaemic and normal blasts. bone marrow were labelled with either the green membrane
The phenotype of the effector cell population was dye F-18 (a kind gift from Dr Radosevic, University of determined by expression of the activation antigen CD69. Twente, The Netherlands) or the red dye PKH-26 (Sigma).
Target cells were labelled with PKH-26 as above and incuThe PKH-26 dye was favoured when it became available bated with non-labelled effector cells in CM at a ratio of because of the greater reliability and speed of labelling.
1:1. Positive control assays were set-up in which PHA (200 Briefly, target cells were thawed rapidly, washed once in ng/ml) was added to the effector cells in the absence of RPMI 1640 supplemented with l-glutamine, penicillin and stimulator cells. After 3-4 h incubation the samples were streptomycin (SFM) and resuspended in PKH cell labelling labelled with a combination of CD69 FITC, CD56 PE and buffer (Sigma). The cells were mixed with an equal volume CD4 or CD8 PerCP (all from Becton Dickinson). Control of 4 mm PKH-26 for 2 min at 21°C. The labelling reaction samples consisted of effector cells incubated with remission was stopped by the addition of an equal volume of neat BMMC (in all cases the level of CD69 expression after FCS for 1 min and the cells were washed twice in SFM incubation with remission BMMC was no greater than that supplemented with 10% FCS (CM). PKH-26-labelled cells of effector cells incubated alone). All samples were set up showed high levels of fluorescence ( Figure 1a as is the CD56 PE signal. CD56 is expressed at relatively but can be resolved from each other in a mixed assay syslow levels compared to the extremely bright fluorescence tem by PKH-26 labelling. The membrane dye was very of the PKH-26 dye. This allows exclusion of the bright stable and there was no transfer to non-labelled effector PKH-26-expressing stimulator cells without loss of the cells during the assay period (data not shown).
CD56 positive effector population. Post-transplant peripheral blood mononuclear cells were suspended in CM and were monocyte-depleted on tissue culture plastic for 2 h at 37°C/5% CO 2 . The non-adherent
Analysis of surface expression of MHC class I molecules
Cryopreserved leukaemic bone marrow samples from each Results allogeneic leukaemic samples from ALL patients. By week 18 post-transplant, the anti-leukaemia activity had fallen but remained detectable. At week 20 post-transplant, no Patient UPN 633 autologous anti-leukaemia activity was detectable although The first post-ABMT sample available from this patient the patient remained in complete remission. The patient was taken at 12 months. Cytotoxicity testing demonstrated relapsed at week 22. Anti-leukaemia activity remained specific anti-leukaemia activity of 24%. Subsequent testing undetectable and he has recently received an allogeneic at 18 and 33 months showed consistent anti-leukaemia BMT from an unrelated volunteer donor. cytotoxicity in the absence of lysis of remission BMMC (Figure 2a) . Analysis of the cellular responders in this assay system as determined by CD69 expression upon co-incuPatient UPN 660 bation showed them to be CD56+ve natural killer cells. There was no increase in activation of CD4 or CD8 T cell Samples received at 1 and 3 months post-ABMT showed high levels of cytolytic activity against both leukaemic and subsets, even when analysis was restricted to CD45RO+ve subsets (Figure 2b) . Furthermore, the absence of activation remission BMMC (Figure 4a) . Samples taken at 6 months showed no cytolytic activity against any targets, including of any cell subset in response to the remission autologous bone marrow supports the leukaemia specificity of this the cell line K562. The patient also lacked detectable numbers of NK cells in her peripheral blood. She relapsed 1 activity. The patient remains in complete remission 38 months post ABMT. complete remission which was consolidated with a second course of FLAG/idarubicin. Three months after relapse she Samples were received from this patient regularly from day 24 post-ABMT. They contained high numbers of activated was commenced on alpha-interferon therapy (IFN␣, 1 and 2 megaUnits alternate days, s.c.) (Schering, Burgess Hill, NK cells at all time points up to 18 weeks post-transplant and he remained in remission. Anti-leukaemia cytotoxic UK). CD56 + cells reappeared in her peripheral blood and she recovered NK cell function. One month after induction activity was detected at 13 weeks post-ABMT in the absence of lysis of autologous remission BMMC (Figure of IFN␣ treatment the patient developed strong leukaemiaspecific lytic activity which has been maintained over the 3). In addition, no activity could be detected against two subsequent 3 months (Figure 4a ). Non-specific lysis of remission BMMC stored prior to ABMT was totally absent in samples taken in second CR (Figure 4a ). She remains in second CR 16 months after reinduction chemotherapy.
Analysis of the responding cell population by CD69 expression showed that the principal early reactivity resided in the CD56 +
/CD8wk
+ cell population (Figure 4b ). In contrast, neither CD56+ve nor CD8+ve cells activated in response to autologous remission BMMC over the same time period (Figure 4c ). The 24-h response appeared to be within the CD56+ve/CD8−ve population. However, this may simply reflect the loss of CD8␣ chain following activation as has been reported for CD8+ve T cells. 17 Stimulation of the PBL with PHA demonstrated that the CD8+ve T cell subset (CD56−ve) was capable of responding, as was the CD4+ve cell subset (Figure 4d) . However, neither cell subset showed increased incidence of CD69 expression after incubation with autologous remission or leukaemic BMMC.
Stimulation with the erythroleukaemic cell line K562, which is a commonly used NK cell target cell, led to the activation of CD56 + /CD8
− NK cells and not the CD56 + /CD8wk cells (Figure 4e ). Immunofluorescent labelling of leukaemic blasts in samples from all patients showed all cells expressed MHC class I molecules and at levels comparable to those expressed by normal peripheral blood myeloid cells (data not shown).
Discussion
Although the graft-versus-leukaemic effect (GVL) after bone marrow transplantation was first identified almost 40 years ago 18 the cellular mediators of this activity in patients remain controversial. The use of T cell depletion (TCD) results from our group 19 demonstrated that TCD with monoclonal antibodies specifically targeted at T cell epitopes combined with effective immunosuppressive pretransplant conditioning can prevent clinical GVHD without increasing the risk of relapse or failure of engraftment. Furthermore, a comprehensive study of multi-centre unrelated donor BMT has confirmed the low incidence of relapse following T cell-specific depletion in contrast with broad spectrum lymphocyte depletion. 20 Indeed, infusions of CD8-depleted donor leukocyte preparations have been used successfully for the treatment of relapse following allogeneic BMT for chronic myeloid leukaemia. 21 These data support a possible role for natural killer cells in the GVL effect.
The role of immune mechanisms in continued remission after ABMT is highly controversial but we have previously shown that some of the immunological consequences of allogeneic BMT can be detected after ABMT. High num- Most recently, a group using a similar dye-exclusion assay leukaemia activity has been reported before, 4 but not in the ABMT setting. In an extensive study of patients with a for cell-mediated killing as used here has demonstrated specific lysis of autologous CLL cells in three of five patients variety of acute leukaemias it was found that the levels of NK cell activity against the NK-sensitive cell line K562 after chemotherapy without BMT. 7 No data were presented on the relationship between this activity and survival. were significantly lower than in normal blood donors.
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Furthermore, this activity increased when the patients were
The results presented here demonstrate the specificity of the anti-leukaemia response and the activation experiments in remission and, in all 15 patients studied longitudinally, a reduction in NK activity to pre-remission levels was assoshow this effect is mediated by NK cells. We have chosen to use two novel assay systems in this study. The flow cytociated with relapse within 10 weeks. These data suggest that functional NK responses may be important in the conmetric cytotoxicity assay was preferred over a standard 51 chromium-release assay since it did not rely upon the trol of residual leukaemic cells but there was no direct evi-assumption that all target cells label equally. This is of mined by antibody labelling. Antibodies specific for HLA-C are poorly defined at present. Thus, while these results particular importance when using clinical samples as target cells in contrast to conventional cell lines, since the popuare consistent with normal expression of MHC class I on the leukaemic blasts it is possible that the specific inhibitory lation is heterogeneous. In a conventional 51 Cr-release assay, target cells are loaded with 51 Cr and incubated with signal through HLA-C may be absent. The identification of GVL activity in the absence of effector cells. The amount of 51 Cr released into the supernatant after a pre-determined period is related to the maxi-GVHD has been a long-term goal of many research groups. We believe that the ABMT setting is ideal for the study of mal amount of The mechanisms by which NK cells respond to target 445-450. cells are currently being elucidated. It appears that NK cells 
